Skip to main content
. Author manuscript; available in PMC: 2018 Jul 23.
Published in final edited form as: J Allergy Clin Immunol Pract. 2017 Oct 31;6(4):1287–1296.e1. doi: 10.1016/j.jaip.2017.09.004

Figure 1.

Figure 1

Representative positive (A. SCAR patient, S1) and negative (B. tolerant control) IFN-γ release ELISpot. Representative CD137 T-cell activation (C.) and positive patch test of (D.) of SCAR patient S1.

Abbreviations: CD3, anti-CD3 antibodies (polyclonal T-cell activator); CEF, peptide pool consisting of 23 viral peptides (EBV, CMV and influenza) which stimulated human CD8+ T cells.

A, IFN-γ release ELISpot of positive SCAR patient. B, IFN-γ release ELISpot of antibiotic tolerant control. Representative images of IFN-γ release spots in 96 well plate in the presence of, (i) CD3 & 200,000 cells/well, media and 200,000 cells/well (unstimulated) and implicated drug (A. SCAR patient) and tolerate drugs (B. Tolerant Control) [left to right of image]. In A, the addition of a physiological control (CEF) is also demonstrated. C, Drug-induced T-cell activation (flow cytometry) from patient demonstrated in A. D, Representation of positive patch test to ceftriaxone 10% for patient represented in 1A and 1C